** U.S.-listed shares of Chinese biopharma co Zai Lab Ltd
ZLAB.O surge 33% to $45 premarket on positive data from a
late-stage study of cancer therapy by partner Novocure NVCR.O
** Novocure shares up 74% at $123 premarket
** Brokerage Jefferies says data is a "positive surprise"
and should help invigorate co's pipeline value
** Brokerage expects ZLAB to submit the data to the Chinese
drug regulator to obtain approval in the country as a
second-line treatment for non-small cell lung cancer
** Novocure had granted ZLAB a license to commercialize the
therapy called Tumor Treating Fields (TTF) in Greater China in
2018
** TTF uses electric fields tuned to specific frequencies to
disrupt cell division, inhibiting tumor growth and causing
affected cancer cells to die
** ZLAB shares had declined 51% in 2022
(Reporting by Leroy Leo in Bengaluru)
((Leroy.Dsouza@thomsonreuters.com ; Twitter: https://twitter.com/LeroyLeo7;))